For example, TAF1B was predicted to be a common inhibitory therapeutic target for ATL, endometrial cancer, T1DM, HC, testicular cancer, tuberculosis and chronic lymphocytic leukemia. This evidence concerns the gene TAF1B and endometrial cancer.